Diabetic Retinopathy Market Analysis Report By Type, By Management, By Region, And Segment Forecasts, 2022-2030
Diabetic Retinopathy Industry Overview
The global diabetic retinopathy market size was valued at USD 6.6 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 6.4% from 2022 to 2030. The rising prevalence of diabetes, growing geriatric population, and increasing prevalence of blindness due to diabetes are among the major factors anticipated to boost market growth over the forecast period. The market is further propelled by the increasing awareness about diabetes management and care and new product launches. Diabetes is a serious and growing problem globally, where the inefficiency of the pancreas to produce insulin results in an increase in blood glucose levels. Diabetic retinopathy is caused by damage to the blood vessels in the retina. This leads to blurred vision and vision loss in most cases.
Risk factors such as high blood sugar levels and poor monitoring of the constant fluctuating BG levels are said to fuel the cause of diabetic retinopathy. Early detection of diabetes in patients, treatment correction, constant self-monitoring by the patients using advanced tools, and adoption of a healthier lifestyle may reduce the damage to the retinal blood vessels, decreasing the prevalence of diabetic retinopathy among patients. Despite all the necessary measures adopted by the diabetic population, diabetic retinopathy can lead to permanent blindness, based on the disease stage and severity of the condition. According to the Department of Assistive and Rehabilitative Services (DARS), Texas, around 78.0% of cases of diabetic retinopathy were reported in 2013 which may eventually lead to loss of vision.
Gather more insights about the market drivers, restrains and growth of the Global Diabetic Retinopathy market
In addition, as per the Royal National Institute of Blind People (RNIB), diabetic retinopathy was among the leading causes of blindness in the U.K. in 2018. Rising patient awareness levels and increasing healthcare expenditure are also among the factors which are likely to propel market growth. Additionally, the WHO claims that the world’s aging population will more than double by 2050, as compared to that in 2020. Hence, it is important to maintain a healthy lifestyle, control obesity, and continuously monitor BG levels in the vulnerable population.
The COVID-19 pandemic impacted the market negatively. Closure of manufacturing units, dramatic economic decline, national lockdowns, shutting of logistic services, and reduced diagnostic activities due to the fear of virus spread were few among the many reasons for the dip in the market. Postponement of sales activities, reduction in R&D activities undertaken by leaders to launch advanced products, and most importantly, economic setbacks experienced by patients led to the dramatic decline in 2020. However, the market is said to bounce back by mid-2022.
Browse through Grand View Research's Medical Devices Industry Research Reports.
- Scar Treatment Market - The global scar treatment market was valued at USD 23.5 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 9.9% from 2023 to 2030.
- Cryoablation Devices Market - Cryoablation devices offer various benefits such as fewer side effects, easy recovery, cost-effective, etc. These benefits represent lucrative growth opportunities for the cryoablation market.
Diabetic Retinopathy Market Segmentation
Grand View Research has segmented the global diabetic retinopathy market based on type, management, and region:
Diabetic Retinopathy Type Outlook (Revenue, USD Million, 2018 - 2030)
- Proliferative diabetic retinopathy
- Non-proliferative diabetic retinopathy
Diabetic Retinopathy Management Outlook (Revenue, USD Million, 2018 - 2030)
- Anti-VEGF
- Intraocular steroid injection
- Laser surgery
- Vitrectomy
Diabetic Retinopathy Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa (MEA)
Key Companies profiled:
Some of the prominent players in the diabetic retinopathy market include:
- Bayer AG
- Allergan plc
- Novartis AG
- Oxurion NV
- Sirnaomics Inc.
- Genentech
- Alimera Sciences
- Ampio Pharmaceuticals
- BCN Peptides
- Kowa Company, Ltd.
Order a free sample PDF of the Diabetic Retinopathy Market Intelligence Study, published by Grand View Research.
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com
Comments
Post a Comment